An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer.

ABSTRACT: A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients treated with either palbociclib or ribociclib referred to our clinical pharmacological counselling, including therapeutic drug monitoring (TDM), pharmacogenetics, and drug-drug interaction analysis to support clinicians in the management of CDKis treatment for metastatic breast cancer. Patients' plasma samples for TDM analysis were collected at steady state and analyzed by an LC-MS/MS method for minimum plasma concentration (C_min) evaluation. Under and overexposure to the drug were defined based on the mean C_min values observed in population pharmacokinetic studies. Polymorphisms in s

SUBMITTER: Roncato R 

PROVIDER: S-EPMC9356076 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature